Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study.

Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Melby TE, Ruff VA

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research15 Nov 2017Cited by 60 (Europe PMC)

PMID29024120DOI10.1002/jbmr.3309PepBankPUB-29024120

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialMechanism
In women with osteoporosis, teriparatide increased cancellous remodeling-based bone formation from baseline.
In plain wordsIn women with osteoporosis, teriparatide increased cancellous remodeling-based bone formation compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCancellous remodeling-based formation
Study
n = 33
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/d · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
All types of formation significantly increased from baseline in the cancellous and endocortical envelopes (differences p < 0.001) with teriparatide (range of changes 2.9- to 21.9-fold), as did MBF in the periosteum (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis received subcutaneous teriparatide (n = 33, 20 μg/d) or denosumab (n = 36, 60 mg once/6 months), open-label for 6 months at 7 US and Canadian sites.
Summary · context
Subjects received double fluorochrome labeling at baseline and before biopsy at 3 months.
Report a problemFND-2902412001
02HumanNon-randomized trialMechanism
In women with osteoporosis, teriparatide increased cancellous modeling-based bone formation from baseline.
In plain wordsIn women with osteoporosis, teriparatide increased cancellous modeling-based bone formation compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCancellous modeling-based formation
Study
n = 33
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/d · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
All types of formation significantly increased from baseline in the cancellous and endocortical envelopes (differences p < 0.001) with teriparatide (range of changes 2.9- to 21.9-fold), as did MBF in the periosteum (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis received subcutaneous teriparatide (n = 33, 20 μg/d) or denosumab (n = 36, 60 mg once/6 months), open-label for 6 months at 7 US and Canadian sites.
Summary · context
Subjects received double fluorochrome labeling at baseline and before biopsy at 3 months.
Report a problemFND-2902412002
03HumanNon-randomized trialMechanism
In women with osteoporosis, teriparatide increased cancellous overflow modeling-based bone formation from baseline.
In plain wordsIn women with osteoporosis, teriparatide increased cancellous overflow modeling-based bone formation compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCancellous overflow modeling-based formation
Study
n = 33
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/d · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
All types of formation significantly increased from baseline in the cancellous and endocortical envelopes (differences p < 0.001) with teriparatide (range of changes 2.9- to 21.9-fold), as did MBF in the periosteum (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis received subcutaneous teriparatide (n = 33, 20 μg/d) or denosumab (n = 36, 60 mg once/6 months), open-label for 6 months at 7 US and Canadian sites.
Summary · context
Subjects received double fluorochrome labeling at baseline and before biopsy at 3 months.
Report a problemFND-2902412003
04HumanNon-randomized trialMechanism
In women with osteoporosis, teriparatide increased endocortical remodeling-based bone formation from baseline.
In plain wordsIn women with osteoporosis, teriparatide increased endocortical remodeling-based bone formation compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEndocortical remodeling-based formation
Study
n = 33
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/d · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
All types of formation significantly increased from baseline in the cancellous and endocortical envelopes (differences p < 0.001) with teriparatide (range of changes 2.9- to 21.9-fold), as did MBF in the periosteum (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis received subcutaneous teriparatide (n = 33, 20 μg/d) or denosumab (n = 36, 60 mg once/6 months), open-label for 6 months at 7 US and Canadian sites.
Summary · context
Subjects received double fluorochrome labeling at baseline and before biopsy at 3 months.
Report a problemFND-2902412004
05HumanNon-randomized trialMechanism
In women with osteoporosis, teriparatide increased endocortical modeling-based bone formation from baseline.
In plain wordsIn women with osteoporosis, teriparatide increased endocortical modeling-based bone formation compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEndocortical modeling-based formation
Study
n = 33
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/d · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
All types of formation significantly increased from baseline in the cancellous and endocortical envelopes (differences p < 0.001) with teriparatide (range of changes 2.9- to 21.9-fold), as did MBF in the periosteum (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis received subcutaneous teriparatide (n = 33, 20 μg/d) or denosumab (n = 36, 60 mg once/6 months), open-label for 6 months at 7 US and Canadian sites.
Summary · context
Subjects received double fluorochrome labeling at baseline and before biopsy at 3 months.
Report a problemFND-2902412005
06HumanNon-randomized trialMechanism
In women with osteoporosis, teriparatide increased endocortical overflow modeling-based bone formation from baseline.
In plain wordsIn women with osteoporosis, teriparatide increased endocortical overflow modeling-based bone formation compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEndocortical overflow modeling-based formation
Study
n = 33
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/d · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
All types of formation significantly increased from baseline in the cancellous and endocortical envelopes (differences p < 0.001) with teriparatide (range of changes 2.9- to 21.9-fold), as did MBF in the periosteum (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis received subcutaneous teriparatide (n = 33, 20 μg/d) or denosumab (n = 36, 60 mg once/6 months), open-label for 6 months at 7 US and Canadian sites.
Summary · context
Subjects received double fluorochrome labeling at baseline and before biopsy at 3 months.
Report a problemFND-2902412006
07HumanNon-randomized trialMechanism
In women with osteoporosis, teriparatide increased periosteal modeling-based bone formation from baseline.
In plain wordsIn women with osteoporosis, teriparatide increased periosteal modeling-based bone formation compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePeriosteal modeling-based formation
Study
n = 33
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/d · subcutaneous · 3 monthsAs given in this study (human).
Source sentences
Summary
All types of formation significantly increased from baseline in the cancellous and endocortical envelopes (differences p < 0.001) with teriparatide (range of changes 2.9- to 21.9-fold), as did MBF in the periosteum (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis received subcutaneous teriparatide (n = 33, 20 μg/d) or denosumab (n = 36, 60 mg once/6 months), open-label for 6 months at 7 US and Canadian sites.
Summary · context
Subjects received double fluorochrome labeling at baseline and before biopsy at 3 months.
Report a problemFND-2902412007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01753856

Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis

Eli Lilly and Companyn = 69Jan 2013 to Jun 2014

Osteoporosis

Trial page ClinicalTrials.govUpdated 8 Oct 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.